Janssen Biotech to work with private company Philogen on molecule-based therapeutics
January 24, 2019Philogen S.p.A’s wholly-owned Swiss subsidiary, Philochem AG, will work with Janssen Biotech to discover new small molecule-based therapeutics utilizing Philochem’s novel lead-generation technologies.
Philogen said in the statement that the collaboration was facilitated by Johnson & Johnson Innovation LLC.
“We are extremely pleased to establish a new collaboration with Janssen, one of the leaders in the discovery and development of novel pharmaceuticals, with an impressive track record in developing small-molecule based therapeutics. We hope our technology will contribute to bringing innovative treatment for serious unmet medical needs,” commented Prof. Dario Neri, co-founder and President of the Scientific Advisory Board of Philogen.
